• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Gregory A. Abel, MD, MPH


  • Herrera AF, Crosby-Thompson A, Friedberg JW, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Millenson MM, Nademanee AP, Niland JC, Rodig SJ, Rodriguez MA, Zelenetz AD, LaCasce AS.Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network.Cancer. 2014 Jul 1(13):1993-9.
  • Odejide OO, Cronin AM, Davidoff AJ, LaCasce AS, Abel GA.Limited Stage Diffuse Large B-Cell Lymphoma: Comparative Effectiveness of Treatment Strategies in a Large Cohort of Elderly Patients.Leuk Lymphoma. 2014 Jun 10:1-27.
  • Abel GA.Public Advertising by Cancer Centers: More Data Needed?.Ann Intern Med. 2014 May 27.
  • Odejide OO, Jacobson JO, Abel GA.Reply to quality control of bone marrow aspirates: Additional steps toward a safer and more efficient procedure.Cancer. 2014 May 1;120(9):1442.
  • Waldman LT, Bean W, Levine AL, Cohen-Bearak A, Phelps FA, Svoboda L, Freedman R, Elfiky A, Berlin S, Abel GA, Deutsch C, Lathan CS.Using FastTrack to Implement an Academic Medical Center and Community Health Center Collaborative for Cancer Care Delivery.Healthcare (Amst). 2013 Dec;1(3-4):130-135.
  • Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN.An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.Blood. 2014 Feb 6;123(6):837-42.
  • Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL.Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.J Clin Oncol. 2014 Feb 1;32(4):306-11.
  • Abel GA, Klaassen R, Lee SJ, Young NL, Cannella L, Steensma DP, Efficace F.Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life.Blood. 2014 Jan 16;123(3):451-2.
  • Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Kelly J, Millenson M, Nademanee AP, Rodriguez MA, Zelenetz AD, Niland J, LaCasce AS, Friedberg JW.Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.British Journal of Haematology. 2013 Nov;163(4):487-95.
  • Evens AM, Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS, Abel GA, Millenson M, Czuczman MS, Rodriguez MA, Niland J, Zelenetz AD, Gordon LI, Friedberg JW.Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.Cancer. 2013 Oct 15;119(20):3662-71.
  • Odejide OO, Cronin AM, DeAngelo DJ, Bernazzoli ZA, Jacobson JO, Rodig SJ, LaCasce AS, Mazeika TJ, Earles KD, Abel GA.Improving the quality of bone marrow assessment: Impact of operator techniques and use of a specimen preparation checklist.Cancer. 2013 Oct 1;119(19):3472-8.
  • Sherman AE, Motyckova G, Fega KR, Deangelo DJ, Abel GA, Steensma D, Wadleigh M, Stone RM, Driver JA.Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes.Leuk Res. 2013 Sep;37(9):998-1003.
  • Warren JL, Harlan LC, Stevens J, Little RF, Abel GA.Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States.J Clin Oncol. 2013 Jun 1;31(16):1984-9.
  • Abou-Nassar KE, Vanderplas A, Friedberg JW, Abel GA, Niland J, Rodriguez MA, Czuczman MS, Millenson M, Crosby A, Gordon LI, Zelenetz AD, Kaminski M, Lacasce AS.Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database.Leuk Lymphoma. 2013 Feb 25.
  • Abel GA, Chen K, Taback N, Hassett MJ, Schrag D, Weeks JC.Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions.Cancer. 2013 Mar 1;119(5):1065-72.
  • Abel GA, Koreth J.Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes.Curr Opin Hematol. 2013 Mar;20(2):150-6.
  • Gray SW, Abel GA.Update on Direct-to-Consumer Marketing in Oncology.J Oncol Pract. 2012 Mar;8(2):124-7.
  • Abel GA.The real world: CLL.Blood. 2011 Mar 31;117(13):3481-2.
  • Friese CR, Earle CC, Magazu LS, Brown JR, Neville BA, Hevelone ND, Richardson LC, Abel GA.Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia.Cancer. 2011 Apr 1;117(7):1470-7.
  • Friese CR, Earle CC, Magazu LS, Brown JR, Neville BA, Hevelone ND, Richardson LC, Abel GA.Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia.Cancer. 2010 Nov 8.
  • Abel GA, Bertrand KA, Earle CC, Laden F.Outcomes for lymphoid malignancies in the Nurses' Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) Program.Hematol Oncol. 2010 Sep;28(3):133-6.
  • Abel GA, Van Bennekom CM, Stone RM, Anderson TE, Kaufman DW.Classification of the myelodysplastic syndrome in a national registry of recently diagnosed patients.Leuk Res. 2010 Jul;34(7):939-41.
  • Abel GA, Burstein HJ, Hevelone ND, Weeks JC.Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment.J Clin Oncol. 2009 Sep 1;27(25):4182-7.
  • Friese CR,Abel GA,Magazu LS,Neville BA,Richardson LC,Earle CC.Diagnostic delay and complications for older adults with multiple myeloma.Leuk Lymphoma. 2009 Mar;50(3):392-400.
  • LaCasce AS,Kho ME,Friedberg JW,Niland JC,Abel GA,Rodriguez MA,Czuczman MS,Millenson MM,Zelenetz AD,Weeks JC.Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network.J Clin Oncol. 2008 Nov 1;26(31):5107-12.
  • Abel GA,Friese CR,Magazu LS,Richardson LC,Fernandez ME,De Zengotita JJ,Earle CC.Delays in referral and diagnosis for chronic hematologic malignancies: a literature review.Leuk Lymphoma. 2008 Jul;49(7):1352-9. Review.
  • Abel GA, Deangelo DJ, Connors JM, Sholl LM, McCaffrey RP, Longtine JA.Clinical JAK2V617F mutation testing: Limited utility for general hospital patients with venous and arterial thromboses in common locations.Am J Hematol. 2008 Jun;83(6):519-20.
  • Abel GA, Glinert LH.Chemotherapy as language: sound symbolism in cancer medication names.Soc Sci Med. 2008 Apr;66(8):1863-9.
  • Abel GA, Lee SJ, Weeks JC.Direct-to-consumer advertising in oncology: a content analysis of print media.J Clin Oncol. 2007 Apr 1;25(10):1267-71.
  • Abel GA, Penson RT, Joffe S, Schapira L, Chabner BA, Lynch TJ.Direct-to-consumer advertising in oncology.Oncologist. 2006 Feb;11(2):217-26.
  • Abel GA, Hays JT, Decker PA, Croghan GA, Kuter DJ, Rigotti NA.Effects of biochemically confirmed smoking cessation on white blood cell count.Mayo Clin Proc. 2005 Aug;80(8):1022-8.
  • Abel GA.Reporting enrollment in clinical trials.Ann Intern Med. 2002 Dec 17;137(12):1007-8; author reply 1007.
  • Sacco RL, Boden-Albala B, Abel G, Lin IF, Elkind M, Hauser WA, Paik MC, Shea S.Race-ethnic disparities in the impact of stroke risk factors: the northern Manhattan stroke study.Stroke. 2001 Aug;32(8):1725-31.
  • Abel GA, Chen X, Boden-Albala B, Sacco RL.Social readjustment and ischemic stroke: lack of an association in a multiethnic population.Neuroepidemiology. 1999;18(1):22-31.